CFTR and cystic fibrosis: Recently, it was shown that the CFTR modulator triple combination therapy with elexacaftor, tezacaftor and ivacaftor (ETI) leads to unprecedented improvements in lung function, body mass index (BMI) and self-reported respiratory symptoms in clinical trials and real-world studies in CF patients with at least one F508del allele (Heijerman et al., 2019; Middleton et al., 2019; Barry et al., 2021; Burgel et al., 2021; Griese et al., 2021; Graeber et al., 2022a; Nichols et al., 2022).